Glutathione

Glutathione is a tripeptide with an unusual gamma-linked glutamate bond that makes it resistant to standard peptidases. Its cysteine thiol is the business end: it donates electrons to neutralise peroxides and free radicals, becoming oxidised glutathione disulfide, which glutathione reductase then recycles using NADPH. It is also the conjugating substrate for phase II detoxification via glutathione S-transferases, which is how the liver handles a great many xenobiotics, and it regenerates vitamins C and E. The skin-lightening effect that drives most consumer demand is real in mechanism — glutathione shifts melanogenesis from eumelanin toward the lighter pheomelanin and inhibits tyrosinase — but the clinical effect from intravenous dosing is modest and temporary. Oral glutathione is largely hydrolysed in the gut, which is the argument for injecting it, though precursor strategies like NAC plus glycine raise intracellular glutathione perfectly well. IN THE BRAIN. Glutathione sits at 1 to 3 mM in brain tissue and is distributed very unevenly: astrocytes hold far more than neurons, and that asymmetry is structural rather than incidental. Neurons import cystine poorly and cannot keep up their own supply, so they depend on a shuttle — astrocytes export glutathione, the ectoenzyme gamma-glutamyl transpeptidase on the astrocyte surface cleaves it to cysteinylglycine, neuronal aminopeptidase N cleaves that to cysteine, and neurons import the cysteine through EAAT3 to synthesise glutathione of their own. A neuron's redox capacity is therefore set by the astrocytes around it. The direct synaptic link is system xc-, the cystine/glutamate antiporter. It imports one cystine and exports one glutamate, which means glutathione synthesis and extrasynaptic glutamate concentration are the same transaction. That extrasynaptic glutamate tone acts on presynaptic mGluR2/3 autoreceptors and damps synaptic glutamate release — the mechanism behind N-acetylcysteine's effects in addiction models, where restoring system xc- function after chronic cocaine normalises glutamate release in the nucleus accumbens. It is also why NAC is not simply an antioxidant in the brain: it changes glutamatergic signalling through a transporter, not through scavenging. Glutathione also reaches the NMDA receptor itself. The receptor carries a redox modulatory site on cysteine residues of its GluN1 and GluN2 subunits, and the reduced-to-oxidised glutathione ratio shifts current through it — reduction potentiates, oxidation attenuates. So the redox state of a synapse is not merely protective housekeeping; it is a gain control on excitatory transmission. The cell type this matters most for is the parvalbumin interneuron. Their firing rate and mitochondrial load make them unusually vulnerable to oxidative stress, and glutathione deficits impair them preferentially — which degrades the gamma oscillations they generate. That is the thread connecting a GCLC risk polymorphism, low brain glutathione measured by magnetic resonance spectroscopy, and cognitive symptoms in schizophrenia, and it is why NAC has been trialled as an add-on there.

Targets: Reactive oxygen species, Glutathione peroxidase, Glutathione S-transferase / phase II detoxification, Tyrosinase and melanogenesis, NMDA receptor redox modulatory site (GluN1/GluN2 cysteines), System xc- cystine/glutamate antiporter (SLC7A11), Astrocyte-neuron cysteine shuttle (GGT, aminopeptidase N, EAAT3), Parvalbumin interneuron redox buffering

• · 600-2400 mg is the usual clinic range. The higher end is typically used for skin protocols. Push slowly — rapid administration is the main cause of the sulfurous taste and nausea people report.
• · 200-600 mg. More practical for self-administration than IV, with a slower absorption curve and less of the acute sulfur reaction.
• · Used in some chronic respiratory protocols. Can trigger bronchospasm in asthmatics — this is a documented reaction, not a theoretical one.

Work out your exact syringe units →

• very commonSulfurous taste or smell during IV administration— Almost universal, rate-dependent, harmless.
• commonNausea
• commonInjection-site stinging
• uncommonBronchospasm with nebulised use— Documented particularly in asthmatics; have a bronchodilator available if nebulising.
• rareRash or hypersensitivity
• rareStevens-Johnson syndrome and toxic epidermal necrolysis— The Philippine FDA issued warnings after severe cutaneous reactions and cases of renal and thyroid dysfunction from unregulated high-dose IV skin-whitening use. This is the one genuinely serious risk with glutathione.

• Asthma or reactive airway disease if nebulising.
• High-dose unregulated IV skin-lightening protocols — this is where the reported deaths and severe cutaneous reactions have come from.
• Pregnancy and breastfeeding for injectable use — no data.

• synergyvitamin-c — Vitamin C regenerates oxidised glutathione; the two are routinely infused together for good reason.
• redundantnac — NAC supplies the rate-limiting cysteine for glutathione synthesis — an oral, cheaper route to the same endpoint.
• cautionchemotherapy — Antioxidant loading during cytotoxic chemotherapy is contested and should not be a self-directed decision.

• · Liver enzymes if using for hepatic indications.
• · Renal function with repeated high-dose IV protocols — renal impairment has been reported in the skin-whitening literature.
• · Skin examination for any new rash, immediately, given the severe cutaneous reaction reports.

Available as a supplement orally; injectable glutathione is compounded rather than FDA-approved, and several national regulators have warned specifically against high-dose IV use for skin whitening.

• Sekhar et al., GlyNAC supplementation and glutathione deficiency in older humans (trial)
• Philippine FDA advisory on intravenous glutathione for skin whitening (guideline)
• Review of glutathione metabolism and therapeutic supplementation (review)

Glutathione is the cell's main thiol reductant and it does three separable jobs. First, direct redox chemistry: the cysteine thiol donates electrons to neutralise peroxides and radicals, becoming the disulfide GSSG, which glutathione reductase then recycles at the cost of NADPH. The ratio of GSH to GSSG is the single most-used index of cellular redox state. Second, conjugation: glutathione S-transferases attach glutathione to electrophilic xenobiotics, which is the core of phase II detoxification and how the liver disposes of a large fraction of everything you are exposed to, including the reactive paracetamol metabolite NAPQI. Third, regeneration of other antioxidants — it recycles oxidised vitamin C and, through that, vitamin E, which is why the vitamin C co-infusion is not merely a clinic upsell. The skin-lightening effect that actually drives consumer demand has a real mechanistic basis: glutathione shifts melanogenesis away from dark eumelanin toward lighter pheomelanin, and inhibits tyrosinase. The problem is not mechanism, it is duration. With a 10-15 minute plasma half-life and no intact cellular uptake, an intravenous dose is a brief spike that is largely dismantled before it can do anything durable, which is consistent with the clinical picture of modest, temporary skin effects requiring continuous repeat dosing. This is where the precursor argument becomes decisive rather than merely cheaper: cysteine is the rate-limiting substrate for glutathione synthesis, and Sekhar's GlyNAC work — supplying glycine and N-acetylcysteine together — demonstrated correction of glutathione deficiency, oxidative stress and multiple ageing-associated defects in older adults in randomised human trials over 16 weeks. That is a stronger human evidence base than injectable glutathione has ever produced, at a fraction of the cost, by giving the cell the raw materials rather than the finished product it cannot import. The central nervous system case is worth separating from the systemic one, because they run on different logic. Systemically, glutathione is a reductant and a conjugation substrate. In the brain it is that as well, but it is also a component of glutamatergic signalling: system xc- makes glutathione synthesis and extrasynaptic glutamate release the same event, and the NMDA receptor's redox site makes the glutathione ratio a gain control on excitatory current. Neither of those is scavenging. Both are reasons a change in glutathione status alters how synapses behave, not merely how much oxidative damage they accumulate. The practical consequence is that route matters more here than almost anywhere else in this reference. Intact glutathione does not cross the blood-brain barrier in useful quantity, so intravenous dosing cannot act on any of the above. Cysteine does cross, which is why precursor strategies — NAC, or NAC with glycine — are the ones with human brain data behind them.

The serious answer first: the reported deaths and severe cutaneous reactions associated with glutathione have come almost entirely from high-dose unregulated intravenous skin-whitening protocols, which is also the largest use of the compound worldwide. Stevens-Johnson syndrome, toxic epidermal necrolysis, renal impairment, thyroid dysfunction, anaphylaxis and a documented case of systemic inflammatory response syndrome within an hour of infusion — these are real reported outcomes and they cluster in that specific setting. Dermatology reviews now state plainly that intravenous glutathione is contraindicated for skin lightening on grounds of both efficacy and safety. If that is why you are buying it, that is the single most important paragraph on this page. Beyond that: the pharmacological futility problem. A 10-15 minute plasma half-life and no intact cellular uptake means that injecting glutathione is a poor way to raise intracellular glutathione, and the precursor route has better human trials behind it at a tiny fraction of the cost. The nebulised route can cause bronchospasm in reactive airways, which is documented rather than theoretical, and people nebulise it without a bronchodilator nearby. And the handling issue is unusually consequential here: glutathione oxidises on contact with air and light, GSSG is not the active species, and a solution that has gone cloudy or discoloured has genuinely converted to something that does not do what you want. Of everything on this list, this is the compound where a visible change in the solution most reliably means the product is spoiled.

1. 200 mgFirst nebulised dose only — 200 mg nebulised, with a bronchodilator available and peak flow measured before and 15 minutes after. Bronchospasm on first exposure in reactive airways is a documented reaction and this is the only genuinely necessary titration step for glutathione.
2. 600 mgSubsequent nebulised doses if step 1 was clean — Up to 600 mg. If there was any fall in peak flow at step 1, do not proceed.

• Reactive oxygen species and peroxides (direct chemistry) — Not a receptor interaction — direct thiol redox chemistry.

  Neutralisation of peroxides and radicals, forming GSSG. The GSH/GSSG ratio is the working definition of cellular redox status.

• Glutathione peroxidase — Obligate co-substrate.

  Reduction of hydrogen peroxide and lipid hydroperoxides. The selenium-dependent enzyme family that does most of the actual peroxide disposal.

• Glutathione S-transferases — Obligate conjugation substrate.

  Phase II detoxification — conjugation of electrophilic xenobiotics for excretion. This is how the liver handles a large fraction of drug and toxin metabolites.

• Tyrosinase and the melanogenesis pathway — Inhibitory; not characterised as a defined binding constant.

  Shifts melanin synthesis from eumelanin toward pheomelanin and inhibits tyrosinase. The real mechanism behind the skin-lightening use, and the reason most glutathione in the world is sold.

• Gamma-glutamyl transpeptidase — Substrate.

  Not a therapeutic target but the reason the therapy is hard — GGT at the cell surface dismantles extracellular glutathione before it can be imported intact.

• System xc- (SLC7A11/SLC3A2 cystine-glutamate antiporter) — Obligate 1:1 exchange; not a classical affinity relationship

  Couples glutathione synthesis to extrasynaptic glutamate release. Raising cystine uptake raises extrasynaptic glutamate, which acts on presynaptic mGluR2/3 and reduces synaptic glutamate release — the mechanism behind NAC's effects on cue-induced drug seeking in animal models.

• NMDA receptor redox modulatory site — Not a binding site in the ligand sense; acts on GluN1/GluN2 cysteine residues

  The reduced-to-oxidised glutathione ratio sets gain on NMDA current. Reduction potentiates, oxidation attenuates, making synaptic redox state a modulator of excitatory transmission rather than only a protective buffer.

• EAAT3 (EAAC1) neuronal cysteine uptake — Cysteine is transported alongside glutamate

  The step by which a neuron obtains the cysteine astrocytes released. Loss of EAAT3 lowers neuronal glutathione specifically, without changing astrocytic levels.

• GlyNAC (glycine plus N-acetylcysteine) supplementation in older adults — randomised clinical trial Randomised clinical trial · n=24 · 16 weeks · 2023

  Correction of glutathione deficiency, oxidative stress, mitochondrial dysfunction and multiple ageing hallmarks in older adults, with 12 young adults as comparators. This is the strongest human evidence in the glutathione space — and it is for oral precursors, not injectable glutathione.

• GlyNAC supplementation in older adults — pilot trial with withdrawal phase Open-label pilot · n=8 · 24 weeks · 2021

  Glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction and body composition, followed by a 12-week withdrawal phase. The withdrawal design is what makes this useful — benefits regressed after stopping, which argues the effect was real rather than drift.

Seconds to minutes into an intravenous push: the sulfurous taste and smell, which is close to universal, rate-dependent and harmless. Minutes: nausea if pushed fast. Ten to fifteen minutes: plasma glutathione is essentially cleared. Any subjective clarity or energy effect people describe is immediate, poorly characterised, and difficult to distinguish from the experience of sitting still in a clinic for an hour. Four to twelve weeks of repeated dosing: the window over which skin-tone changes are reported for lightening protocols — modest and temporary, requiring continued dosing to maintain. Eight to sixteen weeks: the timescale on which the GlyNAC precursor trials moved oxidative stress and mitochondrial markers in older adults, which is the closest thing to a validated timeline in this space.

Vitamin C is a genuine synergy rather than a clinic upsell: ascorbate regenerates oxidised glutathione and the two operate in the same recycling loop, which is why they are routinely co-infused. NAC is the important comparison rather than a stack partner — it supplies the rate-limiting cysteine for glutathione synthesis, it is oral, it costs almost nothing, and combined with glycine it has better human trial evidence than injectable glutathione does. Running IV glutathione and oral NAC together is not wrong, but if you are doing that you should ask why you are paying for the infusion. The interaction that requires actual caution is with cytotoxic chemotherapy: antioxidant loading during chemotherapy is genuinely contested in oncology, plausible arguments exist in both directions, and it should not be a self-directed decision. Alpha-lipoic acid and selenium both feed the same redox machinery and are commonly stacked with no clear evidence of additive benefit. Finally, be aware that if you are running glutathione for skin lightening alongside other unregulated injectables, the severe cutaneous reactions reported in that literature come from exactly that context — high dose, repeated, unregulated product, often multiple agents at once.

Against NAC plus glycine (GlyNAC): this is the comparison that decides the question. GlyNAC has randomised human trials in older adults showing correction of glutathione deficiency and improvement across multiple ageing hallmarks, plus a mouse lifespan result, and it costs almost nothing. Injectable glutathione has small mixed trials, a short half-life that undermines its rationale, and a documented safety signal at high dose. If your goal is intracellular glutathione, the precursors win on evidence, cost and safety simultaneously — that is not a close call. Against intravenous NAC as an approved paracetamol antidote: that is a genuinely evidence-based use of this pathway and worth knowing exists, but it is an acute antidote protocol, not a wellness intervention. Against the skin-lightening market: dermatology has moved to stating that intravenous glutathione is contraindicated for this indication. Topical formulations have a better risk profile and modest evidence. Against other antioxidant infusions: high-dose vitamin C has its own literature and its own problems; the general principle that indiscriminate antioxidant loading is beneficial has not held up well over two decades of trials. Against doing nothing: for someone with documented glutathione deficiency — which is common in ageing and in HIV — correcting it has human evidence behind it. Correcting it by injection specifically does not.

$40–$1200/month. Not verified against live pricing this session. Self-administered subcutaneous or intramuscular glutathione from research-grade powder at 200-600 mg two to three times weekly sits at the low end. Clinic intravenous infusions at 600-2400 mg one to three times weekly, often bundled with vitamin C, reach the top of this range. For comparison, the GlyNAC regimen with the actual human trial data behind it is oral N-acetylcysteine plus glycine, which costs a small fraction of any of this.

• ?Subcutaneous and intramuscular bioavailability of glutathione have not been formally measured.
• ?The 10-15 minute plasma half-life figure comes from the general pharmacology literature; I did not resolve a primary human pharmacokinetic study for it in this session.
• ?Volume of distribution, protein binding and clearance figures are not established for administered glutathione.
• ?Whether injectable glutathione raises intracellular glutathione at all, in any tissue, at clinic doses, has not been convincingly demonstrated.
• ?The severe cutaneous reaction reports come largely from unregulated settings where product purity, endotoxin contamination and co-administered agents cannot be excluded as contributors — the causal contribution of glutathione itself is not cleanly established.
• ?The Philippine FDA advisory referenced in the Core record is real to the best of my knowledge but I did not resolve the primary regulatory document in this session; the peer-reviewed safety literature cited here is what I verified.
• ?No head-to-head trial of injectable glutathione versus oral precursors exists.
• ?Cost figures are estimates and were not verified against live clinic or vendor pricing.
• ?The titration ladder given covers only the nebulised route, because that is the only route where a documented first-dose hazard justifies one.
• ?Whether intravenous or liposomal glutathione raises brain glutathione in humans has not been demonstrated. The barrier argument says it should not, and no imaging study shows that it does.
• ?A distinct 'glutathione receptor' has been proposed on the basis of glutathione displacing glutamate binding, and it remains contested. The system xc- and NMDA redox-site mechanisms are on much firmer ground and do not require it.
• ?The GlyNAC work is real but small, largely from one group, and mostly open-label. The oxidative-stress and mitochondrial markers move convincingly; the cognitive endpoints are softer and need independent replication.
• ?NAC add-on trials in schizophrenia have produced modest and inconsistent effects. The parvalbumin-interneuron mechanism is well supported in animals; whether correcting glutathione in an established illness reverses anything is unresolved.

• Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV, Clinical and Translational Medicine, 2021 · PMID 33783984

  The pilot that started the GlyNAC programme — 24 weeks of supplementation plus a 12-week withdrawal phase in older adults. The withdrawal design is the strongest part of it.

• Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves multiple hallmarks of aging: a randomized clinical trial Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV, The Journals of Gerontology, Series A, 2023 · PMID 35975308

  The randomised follow-up — 24 older adults over 16 weeks with 12 young comparators. This is the trial to cite when someone asks whether raising glutathione does anything in humans. Note again that it is oral precursors, not injections.

• GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, muscle strength, cognitive decline, and body composition: implications for healthy aging Sekhar RV, The Journal of Nutrition, 2021 · PMID 34587244

  The programme review pulling the human and animal work together, including the mechanistic argument for why cysteine and glycine availability, not extracellular glutathione, is the limiting factor.

• Systemic inflammatory response syndrome following high-dose intravenous glutathione Sharma D, et al., Cureus, 2025 · PMID 40556995

  A documented case of shock and fever within an hour of high-dose intravenous glutathione, with endotoxin contamination or supraphysiological glutathione effects both raised as candidate causes. Worth reading before an unregulated infusion.

• Glutathione as a skin-lightening agent and in melasma Sarkar R, et al., International Journal of Dermatology, 2025 · PMID 39444151

  A dermatology review stating plainly that intravenous glutathione is contraindicated for skin lightening due to lack of efficacy and side effects. This is the specialty consensus, and it contradicts the entire commercial market for the compound.

• Exploring the safety and efficacy of glutathione supplementation for skin lightening Alzahrani TF, et al., Cureus, 2025 · PMID 40013212

  Reviews the safety signal specifically — anaphylaxis and hepatotoxicity associated with intravenous use.

• Glutathione in skin aging and tissue regeneration Stanescu C, et al., Molecules, 2026 · PMID 41900080

  Current review noting that injectable glutathione raises systemic levels rapidly but with short-lasting effects and safety concerns — the concise statement of the pharmacological problem.

• GlyNAC supplementation in mice increases length of life by correcting glutathione deficiency, oxidative stress, mitochondrial dysfunction, abnormalities in mitophagy and nutrient sensing, and genomic damage Kumar P, Osahon OW, Sekhar RV, Nutrients, 2022 · PMID 35268089

  The mouse lifespan result — GlyNAC-supplemented mice lived 24% longer than controls. Animal data, but it is the mechanistic bridge between the biomarker corrections and a longevity claim.